These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37601665)

  • 1. Case Report: A case of complete response to entrectinib in
    Moriyama E; Nagasu S; Tanaka T; Shimotsuura Y; Ono T; Umeno H; Akiba J; Kawahara A; Fujita F; Kawaguchi T; Miwa K
    Front Oncol; 2023; 13():1247435. PubMed ID: 37601665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world experience of tropomyosin receptor kinase inhibition with entrectinib in ETV6-NTRK3 positive metastatic salivary secretory carcinoma: A case series.
    Yokota T; Yukino H; Doi M; Ohori H
    Head Neck; 2023 May; 45(5):E10-E15. PubMed ID: 36924196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of an ETV6-NTRK3 rearrangement with unusual, but highly significant FISH signal pattern in a secretory carcinoma of the salivary gland: a case report.
    Wagner F; Greim R; Krebs K; Luebben F; Dimmler A
    Diagn Pathol; 2021 Aug; 16(1):73. PubMed ID: 34372873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report.
    Ernst MS; Lysack JT; Hyrcza MD; Chandarana SP; Hao D
    Curr Oncol; 2022 May; 29(6):3933-3939. PubMed ID: 35735423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib.
    Wu WC; Chen MH
    Front Oncol; 2022; 12():1031396. PubMed ID: 36703785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib.
    Florou V; Nevala-Plagemann C; Whisenant J; Maeda P; Gilcrease GW; Garrido-Laguna I
    J Natl Compr Canc Netw; 2021 May; 19(5):478-482. PubMed ID: 34030125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
    Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion.
    Mortensen L; Ordulu Z; Dagogo-Jack I; Bossuyt V; Winters L; Taghian A; Smith BL; Ellisen LW; Kiedrowski LA; Lennerz JK; Bardia A; Spring LM
    Oncologist; 2021 Oct; 26(10):818-824. PubMed ID: 34176200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The First Reported Case of Neurotrophic Tyrosine Receptor Kinase Fusion-Positive Thymoma Treated Successfully With Entrectinib.
    Salame H; Mckey R; Ballout M; Saad W
    Cureus; 2021 Dec; 13(12):e20588. PubMed ID: 35103164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis.
    Cui Z; Zhai Z; Xie D; Wang L; Cheng F; Lou S; Zou F; Pan R; Chang S; Yao H; She J; Zhang Y; Yang X
    Front Pharmacol; 2024; 15():1329409. PubMed ID: 38357305
    [No Abstract]   [Full Text] [Related]  

  • 11. ETV6-NTRK2 Fusion in a Patient With Metastatic Pulmonary Atypical Carcinoid Successfully Treated With Entrectinib: A Case Report and Review of the Literature.
    Zhang W; Tian S; Li X; Chen Y; Wang X; Zhang Y; Lv L; Li Y; Shi H; Bai C
    Clin Lung Cancer; 2024 May; 25(3):215-224.e3. PubMed ID: 38584068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ETV6-NTRK3-positive parotid mammary analogue secretory carcinoma: a case report.
    Rodríguez Cobo J; Lazuén Fernández S; Mayorga Fernández MM; Gómez Román J; Freire Salinas J; Rodríguez Duque MS; Vallejo Secadas C; Álvarez Gama J; Ibaseta Fidalgo E; Medina Del Valle J
    Rom J Morphol Embryol; 2021; 62(1):309-312. PubMed ID: 34609437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
    Drilon A; Li G; Dogan S; Gounder M; Shen R; Arcila M; Wang L; Hyman DM; Hechtman J; Wei G; Cam NR; Christiansen J; Luo D; Maneval EC; Bauer T; Patel M; Liu SV; Ou SH; Farago A; Shaw A; Shoemaker RF; Lim J; Hornby Z; Multani P; Ladanyi M; Berger M; Katabi N; Ghossein R; Ho AL
    Ann Oncol; 2016 May; 27(5):920-6. PubMed ID: 26884591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of Entrectinib in a Patient With the First Reported
    Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC).
    Chu YH; Dias-Santagata D; Farahani AA; Boyraz B; Faquin WC; Nosé V; Sadow PM
    Mod Pathol; 2020 Nov; 33(11):2186-2197. PubMed ID: 32457407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case report.
    Suzuki K; Harada H; Takeda M; Ohe C; Uemura Y; Kawahara A; Sawada S; Kanda A; Sengupta B; Iwai H
    BMC Med Genomics; 2022 Jan; 15(1):6. PubMed ID: 34991563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands.
    Boon E; Valstar MH; van der Graaf WTA; Bloemena E; Willems SM; Meeuwis CA; Slootweg PJ; Smit LA; Merkx MAW; Takes RP; Kaanders JHAM; Groenen PJTA; Flucke UE; van Herpen CML
    Oral Oncol; 2018 Jul; 82():29-33. PubMed ID: 29909898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding the Molecular Spectrum of Secretory Carcinoma of Salivary Glands With a Novel VIM-RET Fusion.
    Skálová A; Banečkova M; Thompson LDR; Ptáková N; Stevens TM; Brcic L; Hyrcza M; Michal M; Simpson RHW; Santana T; Michal M; Vaněček T; Leivo I
    Am J Surg Pathol; 2020 Oct; 44(10):1295-1307. PubMed ID: 32675658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: A Case Report.
    Dawood S; Ali ZJ
    Case Rep Oncol; 2023; 16(1):1451-1459. PubMed ID: 38028569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report.
    Damásio I; Simões-Pereira J; Donato S; Horta M; Cavaco BM; Rito M; Gomes P; Leite V
    Eur Thyroid J; 2023 Feb; 12(1):. PubMed ID: 36378538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.